CAMP4 Therapeutics Corporation - Common Stock (CAMP)

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and Camp4 Therapeutics each made their public debut.